Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 2/20 | 0.64 |
| ▸ | F7 | P08709 | 1/20 | 0.51 |
| ▸ | F3 | P13726 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.50 |
| ▸ | AVPR1A | P37288 | 2/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | HAT1 | O14929 | 6/20 | 0.44 |
| ▸ | EP300 | Q09472 | 6/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24067322 | 0.88 | F7 (0.69) | NR4A2F7F3ALDH1A1KMT2A | |
| SCHEMBL25742053 | 0.85 | NR4A2 (0.62) | NR4A2F7F3ALDH1A1KMT2A | |
| SCHEMBL13533568 | 0.83 | NR4A2 (0.63) | NR4A2ALDH1A1KMT2AHTR2AHAT1 | |
| SCHEMBL25742059 | 0.82 | NR4A2 (0.58) | NR4A2ALDH1A1KMT2AHAT1EP300 | |
| SCHEMBL3182218 | 0.82 | NR4A2 (0.69) | NR4A2F7F3ALDH1A1GPR84 | |
| SCHEMBL613332 | 0.82 | F7 (0.74) | NR4A2F7F3ALDH1A1KMT2A | |
| SCHEMBL30392504 | 0.82 | F7 (0.74) | NR4A2F7F3ALDH1A1KMT2A | |
| SCHEMBL3181708 | 0.81 | GPR84 (0.50) | NR4A2ALDH1A1KMT2AGPR84HTR2A | |
| SCHEMBL3174938 | 0.81 | NR4A2 (0.49) | NR4A2ALDH1A1KMT2A | |
| Ammonia Solution, Strong SCHEMBL4556453 | 0.80 | F7 (0.72) | NR4A2F7F3ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230121337-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS, INC. | 2023-04-20 | — | — | US | disclosed |
| US-20100016371-A1 | Indole Compounds | GLAXO GROUP LIMITED (GB) | 2010-01-21 | — | — | US | disclosed |
| US-20100016371-A1 | Indole Compounds | GLAXO GROUP LIMITED (GB) | 2010-01-21 | — | — | US | disclosed |
| US-20100016371-A1 | Indole Compounds | GLAXO GROUP LIMITED (GB) | 2010-01-21 | — | — | US | disclosed |
| US-20090298866-A1 | Indole Compounds | GLAXO GROUP LIMITED (GB) | 2009-12-03 | — | — | US | disclosed |
| US-20090298866-A1 | Indole Compounds | GLAXO GROUP LIMITED (GB) | 2009-12-03 | — | — | US | disclosed |
| US-20090298866-A1 | Indole Compounds | GLAXO GROUP LIMITED (GB) | 2009-12-03 | — | — | US | disclosed |
| EP-2044062-A1 | INDOLE COMPOUNDS | Glaxo Group Limited (GB) | 2009-04-08 | — | — | EP | disclosed |
| EP-2041086-A1 | INDOLE COMPOUNDS | Glaxo Group Limited (GB) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008006793-A1 | INDOLE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-01-17 | — | — | WO | disclosed |
| WO-2008006790-A1 | INDOLE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-01-17 | — | — | WO | disclosed |
| WO-2008006790-A1 | INDOLE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-01-17 | — | — | WO | disclosed |
| WO-2008006793-A1 | INDOLE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230121337-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CDK2, CDK20, CDK2AP2 | NR4A2 3309/4885F7 4544/4885F3 3345/4885 |
| US-20100016371-A1 | Indole Compounds | IDO1, TPH1, IDO2 | NR4A2 3552/4885F7 1002/4885F3 116/4885 |
| US-20090298866-A1 | Indole Compounds | IDO1, TPH1, IDO2 | NR4A2 3518/4885F7 900/4885F3 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.